- Thinly traded NuCana (NCNA +59%) is up big, albeit on modest volume, on the heels of its announcement of encouraging interim data from a Phase 1b clinical trial assessing lead candidate Acelarin, combined with the chemo agent cisplatin, for the first-line treatment of advanced biliary tract cancer. The results were presented at the ASCO-GI Symposium in San Francisco.
- Patients receiving Acelarin and cisplatin on days one and eight of a three-week cycle showed a disease control rate of 63% (n=5/8), including one complete responder, three partial responders and one with stable disease. The one with stable cancer was initially considered unsuitable for surgical resection but was subsequently operated on with complete tumor removal.
- The company says lead candidate Acelarin is designed to replace the chemo agent gemcitabine in certain cancers by virtue of its ability to overcome key cancer resistance mechanisms. It is based on its ProTide technology which improves the effectiveness and safety profile of common chemo agents.
- Previously: Mid-stage study underway for NuCana's Acelarin in platinum-resistant ovarian cancer (Nov. 15, 2017)
- Now read: NuCana: This Recent IPO Could Have A Stellar 2018
Original article